External beam radiotherapy in patients with glioblastoma, 5 years experience.

Abstract

Objective: To evaluate overall survival (OS) in patients with glioblastoma (GB) treated with external beam radiotherapy (EBRT) plus concurrent chemotherapy (CT), who attended the Radiotherapy Service Dr. Enrique Gutiérrez at the Medical Teaching Center La Trinidad, Miranda State, during the period from January 2018 to December 2023. Methods: 36 patients from 2018 to 2023 who met the inclusion criteria and were treated with EBRT and concurrent CT were selected. Results: A population of 36 patients was evaluated; the median age was 61 years. 50% of patients received conventional fractionation (6000cGy). 91.7% of patients underwent concurrent RTCT treatment with temozolomide (TMZ). Complications were evaluated according to the fractionation used; only 9 patients had grade 2 neurological complications. In the descriptive analysis, 33 patients died from the disease with a median survival of 9.4 months. 8 patients had local recurrence, with a median time of 14.9 months. Conclusion: Our results demonstrate that administration of concurrent RTCT with TMZ followed by maintenance TMZ remains the standard treatment for GB; however, OS rates remain low, so it is suggested to conduct more studies of this type to achieve better quality of life for our patients.